Stansky reports major TriSalus (TLSI) stock and warrant holdings on Form 3

Rhea-AI Filing Summary

TriSalus Life Sciences director Michael P. Stansky reported his existing ownership in a new Form 3 filing. He beneficially owns 543,232 shares of TriSalus common stock and a warrant exercisable for 827,500 shares of common stock at an exercise price of $11.50 per share, expiring on August 10, 2028.

The filing also reports 82,500 shares of common stock owned by Skyview Investments LLC, where Stansky is the managing member and exercises voting and dispositive power. All of these securities were acquired before he became a director, effective February 4, 2026.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Stansky Michael P

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER CO 80031

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/04/2026

3. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	543,232(1)	D
Common Stock	82,500(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant	08/10/2023	08/10/2028	Common Stock	827,500(1)	$11.5	D

Explanation of Responses:

1. The securities reported herein were acquired by the Reporting Person prior to the Reporting Person becoming a director of the issuer. The Reporting Person was appointed as a director of the Issuer effective February 4, 2026.

2. The securities reported herein are owned by Skyview Investments LLC. Mr. Stansky serves as managing member of Skyview Investments LLC (and in such capacity may be deemed to beneficially own the securities reported herein). Voting and dispositive power over the securities owned by Skyview Investments LLC is exercised in his capacity as managing member.

Remarks:

	/s/ Michael P. Stansky	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider holdings did Michael P. Stansky report in TriSalus Life Sciences (TLSI)?

Michael P. Stansky reported beneficial ownership of 543,232 TriSalus common shares and a warrant for 827,500 shares at $11.50 per share, expiring August 10, 2028. He also reported 82,500 shares held by Skyview Investments LLC, where he is managing member.

When did Michael P. Stansky become a director of TriSalus Life Sciences (TLSI)?

Michael P. Stansky became a director of TriSalus Life Sciences effective February 4, 2026. The Form 3 notes that all reported securities, including common stock and warrants, were acquired before his appointment as a director of the company on that effective date.

What warrant position did Michael P. Stansky disclose for TriSalus Life Sciences (TLSI)?

He disclosed a warrant covering 827,500 shares of TriSalus common stock with an exercise price of $11.50 per share. The warrant became exercisable on August 10, 2023 and is scheduled to expire on August 10, 2028, according to the Form 3.

How many TriSalus (TLSI) shares are held through Skyview Investments LLC?

The Form 3 reports 82,500 TriSalus common shares owned by Skyview Investments LLC. Michael P. Stansky serves as managing member of Skyview and, in that capacity, may be deemed to beneficially own these shares with voting and dispositive power.

Did Michael P. Stansky acquire his TriSalus (TLSI) securities after joining the board?

No. The Form 3 states the securities were acquired before he became a director. His appointment as a director became effective on February 4, 2026, and the filing simply reports his existing ownership positions as of that date.

Does Michael P. Stansky report direct or indirect ownership of TriSalus (TLSI) shares?

He reports direct beneficial ownership of 543,232 common shares and the 827,500-share warrant. Additionally, 82,500 common shares are owned by Skyview Investments LLC, where he is managing member and exercises voting and dispositive power over those securities.